Video

Dr. Moul on Impact of Obesity in Active Surveillance

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

The guidelines for following up on active surveillance, such as how often a biopsy should be performed and where molecular markers may fit in, can be challenging, Moul explains. Previous data suggest that, following a radical prostatectomy, obese men have a higher risk of disease recurrence. This study, led by Moul, examined the impact of obesity on men undergoing active surveillance for prostate cancer.

Researchers found that obese men may have a higher risk of disease recurrence on active surveillance. Additionally, their disease could be of a higher grade when analyzed on a repeat biopsy.

Though this is preliminary data, Moul suggests that obese men may not be as ideal candidates for active surveillance as men with a normal body mass index.

<<<

View more from the 2015 AUA Annual Meeting

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD